{"analyses":[{"ciLowerLimit":"0.32","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.82","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0043","paramType":"Hazard Ratio (HR)","paramValue":"0.51","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit not reached","groupId":"OG000","lowerLimit":"6.54","upperLimit":"NA","value":"10.25"},{"groupId":"OG001","lowerLimit":"2.83","upperLimit":"7.62","value":"4.70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"57"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization to the date of the first documented tumor progression or death due to any cause. Progressive disease response criteria were defined as an increase of 25% from lowest response value in any one or more of the following:\n\n1\\. Serum M-component and/or 2. Urine M-component and/or 3. Only in patients without measurable serum and urine M-protein levels: the difference between involved and uninvolved FLC levels 4. Bone marrow plasma cell percentage; Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia that can be attributed solely to the plasma cell proliferative disorder","dispersionType":"95% Confidence Interval","groups":[{"description":"Elotuzumab + Pomalidomide + Dexamethasone","id":"OG000","title":"E-Pd Cohort"},{"description":"Pomalidomide + Dexamethasone","id":"OG001","title":"Pd Cohort"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to date of progression or death (up to approximately 21 months)","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}